ANTI-SARS-CoV-2 SEROCONVERSIO IN IMMUNE-MEDIATED KIDNEY DISEASES

This is a multicentric, observational, retrospective study. The primary endpoint of the study is to investigate the humoral immunological response to SARS-Cov-2 vaccination in this population, looking for clinical features predisposing to seroconversion failure. Secondary endpoints are * to investigate the appearance of symptomatic SARS-CoV-2 infection, despite vaccination, looking for any clinical features predisposing to infection, * to identify the protective cut-off of antibody titer against SARS-CoV-2 infection. Each study participating center will select all vaccinated patients with immune-mediated renal diseases for whom anti-COVID serology will be available.